Last reviewed · How we verify
NCT04445363: AA
A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata
Phase 1, PHASE2 trial testing Jaktinib hydrochloride cream in Alopecia Areata(AA) in 160 participants. Status unknown.
1 December 2024
Quick facts
| Lead sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 160 |
| Start date | 12 August 2020 |
| Primary completion | 1 December 2024 |
| Estimated completion | 1 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Jaktinib hydrochloride cream
- Placebo
Conditions studied
- Alopecia Areata(AA) — all drugs for Alopecia Areata(AA) →
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd — full company profile →
Who can join
Adults 18 to 65, any sex, with Alopecia Areata(AA). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study includes a dose escalation part(phase I) and a dose extension part(phase II).
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y, Alexander M, Gadina M, O'Shea JJ, et al · · 2021 · cited 92× · PMID 34625141 · DOI 10.1016/j.jaci.2021.08.004 -
Inhibition of T-cell activity in alopecia areata: recent developments and new directions.
Passeron T, King B, Seneschal J, Steinhoff M, et al · · 2023 · cited 54× · PMID 38022501 · DOI 10.3389/fimmu.2023.1243556 -
Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I, Pikiewicz W, Kaminiów K. · · 2023 · cited 6× · PMID 38138551 · DOI 10.3390/molecules28248064
Verify or expand the search:
- PubMed search for NCT04445363
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alopecia Areata(AA)
Currently open trials in the same condition.
- NCT07381556 — Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study · Phase 4 · recruiting
- NCT07049328 — HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata · Phase 1 · recruiting
Other Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials
Trials by the same sponsor.
- NCT05279001 — A Safety and Tolerability Study of Jaktinib · Phase 1 · unknown
- NCT06193148 — A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants · Phase 1 · completed
- NCT06132243 — Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions · Phase 1 · completed
- NCT05864573 — Study of ZGGS15 in Patients With Advanced Solid Tumors · Phase 1 · completed
- NCT05584800 — Study of ZGGS18 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04445363 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Last refreshed: 6 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04445363.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing